2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

October 15, 2026

Dana-Farber

1

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss results from the PANKU-Breast02 study.
2

PANKU-Breast02 evaluated izalontamab brengitecan, also called iza-bren.
3

Iza-bren is described as a dual-antibody drug conjugate.
4

The study concerns metastatic triple-negative breast cancer.
5

The provided context does not report the study’s results or efficacy and safety findings.